Bristol Myers Squibb stock: Q3 sales beat lifts 2026 outlook

Published on 10/30/2026 at 16:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock follows a quarterly revenue beat and a higher 2026 sales outlook. Adjusted earnings guidance moved lower after deal-related charges.

Quarterly growth meets earnings pressure

Third-quarter revenue exceeded expectations as the Growth Portfolio expanded.
Management raised the full-year sales range but lowered adjusted earnings guidance.
Higher charges and a lower adjusted gross margin remain important investor considerations.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb reported third-quarter 2026 results on Thursday, October 29, with revenue and adjusted earnings above analyst expectations. The company raised its full-year sales forecast but lowered its adjusted earnings outlook because of acquired in-process research and development charges and licensing income, according to Yahoo Finance.

Sales growth lifts the outlook

Revenue increased 7 percent year over year to USD 13.07 billion, topping the cited analyst estimate of USD 12.72 billion. Adjusted earnings reached USD 1.35 per share against a consensus estimate of USD 1.09.

The Growth Portfolio generated USD 7.7 billion in revenue, up 12 percent year over year, supported by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag. The Legacy Portfolio produced USD 5.4 billion, an increase of 1 percent, while Eliquis revenue rose 25 percent to USD 4.69 billion.

Charges cloud the earnings view

Bristol Myers Squibb lifted its 2026 revenue guidance to USD 49.75 billion to USD 50.25 billion from USD 49.0 billion to USD 50.0 billion previously. At the same time, adjusted EPS guidance was set at USD 6.35 to USD 6.55, including a negative USD 0.60 per-share impact from acquired IPRD charges and licensing income.

Adjusted gross margin fell to 68.4 percent from 72.9 percent in the year-earlier quarter. The company attributed the decline primarily to product mix changes and a one-time charge linked to the termination of a contract, leaving investors to weigh stronger sales against lower near-term earnings visibility.

Bristol Myers Squibb stock traded at 56.35 euros on Lang & Schwarz at 16:06:16 CEST on Friday, October 30, 2026; the real-time quote of Bristol Myers Squibb stock is available for ongoing monitoring.